4.42

2.22% -0.16

After Hours: 4.48 0.06 +1.36%

Minerva Neurosciences Inc (NERV)

Overview News Price History Financials Discussions Forecast Stock Split

Minerva Neurosciences Inc stock is traded at $4.42, with a volume of 93,809. It is down -2.22% in the last 24 hours and up +4.88% over the past month. Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Previous Close:

$4.58

Open:

$4.54

24h Volume:

93,809

Relative Volume:

0.42

Market Cap:

$211.04M

Revenue:

Net Income/Loss:

$-293.42M

P/E Ratio:

-0.1516

EPS:

-29.1639

Net Cash Flow:

$-14.87M

1W Performance:

-3.07%

1M Performance:

+4.88%

6M Performance:

-30.57%

1Y Performance:

+99.03%

1-Day Range:

$4.40

$4.58

1-Week Range:

$3.84

$4.79

52-Week Range:

$1.93

$12.46

Minerva Neurosciences Inc Stock (NERV) Company Profile

Name

Minerva Neurosciences Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-600-7373

Address

1500 DISTRICT AVENUE, BURLINGTON, MA

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

NERV's Discussions on Twitter

Compare NERV vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NERV Minerva Neurosciences Inc	4.42	218.68M	0	-293.42M	-14.87M	-29.16
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Citizens	Mkt Outperform
Jun-08-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Initiated	BTIG Research	Buy
Oct-02-19	Reiterated	Chardan Capital Markets	Buy
Sep-25-19	Initiated	Chardan Capital Markets	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-31-19	Initiated	H.C. Wainwright	Buy
Sep-01-17	Initiated	Citigroup	Buy
Mar-06-17	Resumed	Jefferies	Buy
May-12-16	Resumed	Jefferies	Buy

View All

Minerva Neurosciences Inc Stock (NERV) Latest News

Aug 14, 2026

NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus

Aug 14, 2026

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - marketbeat.com

Aug 14, 2026

Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada

Aug 14, 2026

Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com

Aug 14, 2026

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan

Aug 14, 2026

Aug 13, 2026

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan

Aug 13, 2026

Aug 12, 2026

Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks

Aug 12, 2026

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan

Aug 12, 2026

HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - marketbeat.com

Aug 12, 2026

Aug 11, 2026

H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo

Aug 11, 2026

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail

Aug 11, 2026

Aug 08, 2026

Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat

Aug 08, 2026

Aug 07, 2026

Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat

Aug 07, 2026

Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria

Aug 07, 2026

Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade

Aug 07, 2026

Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView

Aug 07, 2026

Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView

Aug 07, 2026

Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan

Aug 07, 2026

Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView

Aug 07, 2026

Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com

Aug 07, 2026

Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative

Aug 07, 2026

Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain - Stock Titan

Aug 07, 2026

Minerva's schizophrenia trial is designed to enroll 380 patients - Stock Titan

Aug 07, 2026

Aug 04, 2026

Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV - MarketBeat

Aug 04, 2026

Aug 03, 2026

Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com - Investing.com Nigeria

Aug 03, 2026

Minerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock Titan

Aug 03, 2026

NERV Q2'26 Earnings: EPS estimate is (0.19) USD - TradingView

Aug 03, 2026

Aug 02, 2026

Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV - marketbeat.com

Aug 02, 2026

Jul 28, 2026